First Phase III Success Opens Up Cardiovascular Pathway For Arrowhead

Arrowhead could have its first in-house RNA therapy on the market by 2025, with big plans to expand its reach in cardiometabolic disease, following a pivotal trial hit.

Arrowhead

Some twenty years since it was founded, Arrowhead Pharmaceuticals has achieved its first Phase III success from its in-house RNA interference platform.

The company has so far been in the shadow of more advanced companies with RNA-based therapies such as Alnylam...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip